The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Site Search
Showing 1 - 3 of 3 results
Press Release
|
|
3 min read
In a letter to California's Assembly Committee on Health, the Cystic Fibrosis Foundation expressed its support for AB 2180, which, if passed, would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements, as well as require covered benefits to be considered essential health benefits.
The Cystic Fibrosis Foundation joined the CDC Coalition in a letter to leaders of the House Appropriation Subcommittee on Labor, Health, Human Services, Education, and Related Agencies, urging them to include $11.581 billion for the Centers for Disease Control and Prevention in the Fiscal Year 2025 budget.